Clinical Trial Update: The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

View source ↗

Summary

The document describes a clinical trial evaluating the efficacy and safety of combining third-generation tyrosine kinase inhibitors with azacitidine and a Bcl-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia in Blast Phase

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Ponatinib (ponatinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Chronic Myeloid Leukemia | Status: RECRUITING